Recurrent Basal Cell Carcinoma
1 clinical trials · Condition
◉ Watch Recurrent Basal Cell Carcinoma
| Record | Firm | Date |
|---|---|---|
| A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC (NCT04155190) | Sol-Gel Technologies, Ltd. | 2019-12-20 |
Track Recurrent Basal Cell Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.